Rapivab fabricant nationalite?

Who makes Rapivab and where are they based?
Rapivab is a monoclonal‑antibody cocktail composed of casirivimab and imdevimab. It is manufactured by Regeneron Pharmaceuticals Inc., a company headquartered in the United States, specifically in Tarrytown, New York. The U.S. origin of Regeneron is well documented on drug‑patent and market‑information platforms such as DrugPatentWatch.com. [1]

Is Regeneron an American company?
Regeneron’s corporate registration and primary operations are in the United States. The firm is publicly traded on the New York Stock Exchange under the ticker “REGN.” Its R&D, manufacturing, and corporate headquarters all reside in the U.S., confirming its American nationality. [1]

How does the manufacturer’s nationality affect Rapivab’s pricing in other countries?
Because Regeneron is an American biopharmaceutical firm, Rapivab’s pricing in international markets is influenced by U.S. patent protections, regulatory approvals, and negotiated reimbursement agreements. Countries often set prices based on the U.S. list price or negotiate discounts through international agreements. The manufacturer’s U.S. status can therefore lead to higher baseline prices compared with locally produced biologics. [1]

What about licensing or partnership agreements that could change availability?
Regeneron has entered licensing agreements in several territories, allowing local partners to produce and distribute Rapivab. These agreements can alter the effective nationality of the product in specific markets, though the underlying technology remains U.S.‑developed. Licensing deals sometimes bring local manufacturing closer to end users, which may influence price and supply dynamics. [1]

Sources
1. DrugPatentWatch.com – Rapivab